OncoMatch/Clinical Trials/NCT05346809
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Is NCT05346809 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Isatuximab for lymphoma.
Treatment: Isatuximab — The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Multiple Myeloma
Hodgkin Lymphoma
Prior therapy
Must have received: autologous stem cell transplant — first ASCT
Patients undergoing first ASCT will be eligible for the study.
Cannot have received: CD38 antibody
Exception: allowed if not within the last 12 months
Previously exposure to a CD38 antibody during the last 12 months.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Karmanos Cancer Institute · Detroit, Michigan
- Columbia University · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify